GN-HEARING
1.2.2021 09:02:06 CET | Business Wire | Press release
GN Hearing, the global leader in hearing aid innovation, today unveils ReSound Key, a full essential hearing aid line-up that provides greater access to proven and award-winning hearing technology worldwide. Based on an advanced chip platform and GN’s Organic Hearing philosophy, ReSound Key promises clear, natural sound quality. It is also packed with the latest technology, such as rechargeable options and state-of-the-art streaming, so that more people can now stay connected to live life to the fullest.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210201005069/en/
Today, only one in five of those who could benefit from hearing aids are using themi , leaving a large proportion to miss out on life’s sounds, communicating with family, and socializing with friends. The long-awaited ReSound Key is set to make a huge difference to people with all types of hearing loss. People can boost their confidence and connect with others and the world during times of social isolation; all with clear sound and leading rechargeability that offers up to 30 hours of power from one charge. They can enjoy direct streaming using iOS and Android™ devices and state-of-the-art Bluetooth® Low Energy.
Not treating hearing loss comes at a personal cost, with implications for physical, social, emotional, and mental health.ii,iii,iv However, professional guidance is at hand, even remotely, thanks to the innovative telehealth solution, ReSound Assist Live. With this agile at-home service, hearing care professionals can program and adjust ReSound Key hearing aids via video consultations to help people grow with their hearing and nurture their relationships.
GN Hearing CEO and President, Gitte Aabo, explains: “At GN Hearing, we believe that everyone deserves great hearing. Treating hearing loss can radically transform lives, helping people to thrive and grow. The launch of ReSound Key gives more people access to the best care and professional guidance, which helps them feel more confident and stay in touch with others to participate fully in life.”
ReSound Key joins the groundbreaking ReSound ONETM with M&RIE* and ReSound LiNX Quattro™ in the strongest and broadest ReSound portfolio yet, which offers premium hearing solutions at all price levels. Now more people can benefit from the company’s long-standing Organic Hearing philosophy to connect with the world around them in the most intuitive and natural way, which is inspired by how the ear works and the natural ways we listen.
Working with intuitive apps, ReSound Key further enhances the individualized hearing experience and can connect to a range of wireless accessories for additional help in challenging listening situations. New integrated, streamlined fitting and software updates ensure a seamless first fit and customer satisfaction. These updates make it easier than ever to offer the ReSound portfolio for users to enjoy.
ReSound Key is available in 10 models, including the popular rechargeable Receiver-in-Ear (RIE) design, custom hearing aids, and Behind-the-Ear (BTE) options – even including high power and super power models for profound hearing loss. ReSound Key will roll out in markets around the world from February 1, 2021. The same technology and models are also available in the new Beltone Rely hearing aid portfolio.
For further information, visit the ReSound Newsroom and learn about the Organic Hearing philosophy. A ReSound Virtual Conference is hosted for hearing care professionals in the United States on February 2, 2021.
– ENDS –
NOTES TO EDITORS
About ReSound
ReSound hearing aids, available from leading hearing care professionals, continue to set worldwide standards for quality and intuitive technology to help people with hearing loss communicate better than ever before. ReSound was the first hearing aid brand to be Made for iPhone, bringing direct streaming from hearing aids into the iPhone era. It also pioneered the development of 2.4 GHz wireless technology and made it possible to receive advanced at-home hearing care during COVID-19. The recent introduction of a new class of hearing technology with ReSound ONE demonstrates that ReSound is the undisputed innovation leader putting people with hearing loss at the center. Featuring award winning technology, ReSound has been trusted for decades by people with hearing loss and their caregivers around the world.
About GN Group
The GN Group enables people to Hear More, Do More and Be More through its intelligent hearing, audio and video collaboration solutions. Inspired by people and driven by our innovation leadership, we leverage technological synergies between our hearing and audio divisions to deliver unique and increasingly individualized user experiences in our products and solutions.
150 years ago, GN was founded with a truly innovative and global mindset. Today, we honor that legacy with world-leading expertise in the human ear, sound and video processing, wireless technology, miniaturization and collaborations with leading technology partners. GN's solutions are marketed by the brands ReSound, Beltone, Interton, Jabra, BlueParrott and FalCom in 100 countries. Founded in 1869, the GN Group employs 6,500 people and is listed on Nasdaq Copenhagen (GN.CO).
Visit our homepage GN.com, get to know our innovation and leadership , and connect with us on LinkedIn and Facebook .
*ReSound ONE introduced the world’s first full-featured hearing aid with M&RIE. Microphone and Receiver In Ear, for a truly individualized, more complete sound experience. ‘Full-featured’ means a microphone in the ear and two additional, standard directional microphones, directionality features and wireless audio streaming.
© 2021 GN Hearing A/S. All rights reserved. ReSound is a trademark of GN Hearing A/S. Beltone is a trademark of GN Hearing Care Corporation. Apple, the Apple logo, iPhone, iPad and iPod touch are trademarks of Apple Inc., registered in the U.S. and other countries. Android is a trademark of Google LLC. Bluetooth word mark and logos are registered trademarks owned by Bluetooth SIG, Inc
i World Health Organization (WHO) 2020: https://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss
ii Hearing loss and incident dementia. Lin et al 2011
iii The impact of communication impairments on the social relationships of older adults: Pathways to psychological well-being. Palmer et al 2019
iv Hearing loss and associated medical conditions among individuals 65 years and older. McKee et al 2018
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005069/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom